United Kingdom
Search    
Include All CSL Behring Country Sites

Who We Are

The CSL Behring story spans decades of innovation, collaboration, patient focus, and an ongoing drive for excellence.

Learn more about us here.
For Healthcare Professionals
CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products including:
null Coagulation therapies
For rapid warfarin reversal, von Willebrand disease, haemophilia and congenital fibrinogen deficiency
null Immunology therapies
For hereditary angioedema, immune deficiency disorders, and haemolytic disease of the newborn
Resource centre for healthcare professionals
For Patients
Rapid warfarin reversal
Von Willebrand Disease
Haemophilia
Congenital Fibrinogen Deficiency
Immune Deficiency Disorders
Hereditary Angioedema
Haemolytic Disease of the Newborn
News
18-Apr-2012
CSL Behring receives MHRA approval for self-administration of ...
17-Apr-2012
CSL Behring Supports World Immunology Day 2012
29-Feb-2012
CSL Behring supports Rare Disease Day 2012
Beriplex® P/N (human prothrombin complex concentrate) dosage app for healthcare professionals
Hizentra®▼(human normal immunoglobulin, SCIg) dosage app for healthcare professionals